Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Paul A. Reilly, Charles V. Pollack, Frank W. Sellke(Brown University), Menno V. Huisman(Leiden University Medical Center), Stephan Glund(Boehringer Ingelheim (Germany)), Thorsten Steiner(Heidelberg University), Jerrold H. Levy(Duke University), Robert Dubiel(Boehringer Ingelheim (Germany)), Pieter W. Kamphuisen(University Medical Center Groningen), Elaine M. Hylek(Boston University), Jeffrey I. Weitz(McMaster University Medical Centre), Bushi Wang(Boehringer Ingelheim (United States)), John W. Eikelboom(Population Health Research Institute), Richard A. Bernstein(Northwestern University), Joachim Stangier(University of Bonn), Joerg Kreuzer(Boehringer Ingelheim (Germany)), CW Kam(Boehringer Ingelheim (Germany))
Cited by 154
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Prevalence of Diagnosed Atrial Fibrillation in Adults
|JAMA|2001|6.2k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k